Large Study Examines Type 1 Diabetes Risk After COVID-19

Researchers across eight countries tracked whether COVID-19 increases the risk of developing Type 1 diabetes and other autoimmune conditions in the months following infection.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

diagnosisscreeningautoantibodiesstaging

Key takeaways

A major international study looked at whether COVID-19 might trigger Type 1 diabetes and other autoimmune diseases during the post-acute phase
The research analyzed electronic health records and medical data from the UK, Netherlands, Norway, Spain, France, Korea, Estonia, and the USA
Patients were followed for up to a year after COVID-19 infection to track new diagnoses of autoimmune and inflammatory conditions
The study also examined whether reinfection with COVID-19 carried additional risks for developing these conditions

Understanding the Question

COVID-19 has raised questions about long-term health effects. One concern is whether the infection might trigger autoimmune diseases—conditions where the immune system attacks the body's own cells—including Type 1 diabetes.

Type 1 diabetes occurs when the immune system damages insulin-producing cells in the pancreas. Researchers wanted to know if COVID-19 could increase the risk of this happening in previously unaffected people.

How the Study Was Designed

This was a large network cohort study involving eight countries: the UK, Netherlands, Norway, Spain, France, Korea, Estonia, and the USA. Researchers used electronic health records, hospital records, and healthcare claims to track what happened to people after COVID-19 infection.

The study followed two main groups: people who tested negative for COVID-19 (the comparison group) and people who had confirmed COVID-19 infections. Researchers tracked patients from September 2020 through the latest available data, following them for up to 365 days after infection to see who developed new diagnoses.

The study also looked at a separate group of people who had COVID-19 more than once, to see if reinfection posed additional risks.

What Conditions Were Examined

The research tracked several autoimmune and inflammatory conditions beyond Type 1 diabetes. These included rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus, and inflammatory bowel disease.

The study also looked for signs of post-acute COVID syndromes like postural orthostatic tachycardia syndrome (POTS) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), as well as multi-inflammatory syndrome.

Why This Matters

Understanding whether COVID-19 increases autoimmune disease risk is important for healthcare providers and patients. If a connection exists, it could help identify people at higher risk and enable earlier detection.

This international study brings together data from millions of health records across different healthcare systems, providing a broad picture of post-COVID health outcomes. Results from this research will help clarify what role, if any, COVID-19 plays in triggering Type 1 diabetes and other autoimmune conditions.

Evidence label

Source: BMJ public health. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.